Adipokines in Pregnancy: A Systematic Review of Clinical Data

Biomedicines. 2023 May 11;11(5):1419. doi: 10.3390/biomedicines11051419.

Abstract

Adipokines are signaling proteins involved in metabolic, endocrinological, vascular and immunogenic processes. Associations of various adipokines with not only insulin resistance but also with increased insulin sensitivity, increased systolic blood pressure, and atherosclerosis highlight the significance of adipokines in several components of metabolic syndrome and metabolic diseases in general. As pregnancy presents a unique metabolic state, the role of adipokines in pregnancy, and even in various pregnancy complications, appears to be key to elucidating these metabolic processes. Many studies in recent years have attempted to clarify the role of adipokines in pregnancy and gestational pathologies. In this review, we aim to investigate the changes in maternal adipokine levels in physiological gestation, as well as the association of adipokines with pregnancy pathologies, such as gestational diabetes mellitus (GDM) and preeclampsia (PE). Furthermore, we will analyze the association of adipokines in both maternal serum and cord blood with parameters of intrauterine growth and various pregnancy outcomes.

Keywords: adipokines; gestational diabetes; intrauterine growth; preeclampsia; pregnancy.

Publication types

  • Review

Grants and funding

This work was supported by grants from the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation—Projektnummer 209933838—SFB 1052) and from Deutsches Zentrum für Diabetesforschung (DZD, Grant: 82DZD00601). This study was further supported by a general research funding grant from the German Diabetes Association (DDG). N.K. was supported by a doctoral studies scholarship from the medical faculty of the University of Leipzig (project number: 990101-113). T.E. was supported by a Novo Nordisk postdoctoral fellowship run in partnership with Karolinska Institutet, Stockholm, Sweden, a Karolinska Institutet Research Foundation grant, the Stiftelsen Stig och Gunborg Westman, the Deutsche Diabetes Gesellschaft (DDG), as well as by the Swedish Kidney Foundation (Njurfonden). T.E. was further funded through the EFSD Mentorship Programme supported by AstraZeneca.